Crescent Biopharma, Inc. (CBIO) vs Nuvectis Pharma, Inc. (NVCT)
A side-by-side comparison of Crescent Biopharma, Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBIO
Crescent Biopharma, Inc.
$14.08HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
NVCT
Nuvectis Pharma, Inc.
$20.62HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
Total return — CBIO vs NVCT
growth of $100 · dividends reinvested · last 5yCBIO -54.9% (-14.7%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window
Log scale — wide-divergence pair
CBIO NVCT
CBIO vs NVCT: by the numbers
- •NVCT is the larger company ($547M vs $523M market cap).
- •Both run net losses; NVCT's is the smaller (0.00% vs -1371.51% net margin).
Metrics side by side
Valuation
| Metric | CBIO | NVCT |
|---|---|---|
| P/S ratio | 44.01 | N/A |
| P/B ratio | 3.28 | 60.25 |
Profitability
| Metric | CBIO | NVCT |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1407.52% | 0.00% |
| Net margin | -1371.51% | 0.00% |
| ROE | -99.83% | -306.61% |
| ROIC | -102.59% | -317.86% |
Growth (annualized)
| Metric | CBIO | NVCT |
|---|---|---|
| Revenue CAGR (5Y) | 39.89% | N/A |
| Total return CAGR (5Y) | -24.40% | N/A |
Go deeper
Dig into the metrics
Crescent Biopharma ROENuvectis Pharma ROECrescent Biopharma operating marginNuvectis Pharma operating marginCrescent Biopharma revenue growthNuvectis Pharma revenue growthCrescent Biopharma free cash flowNuvectis Pharma free cash flow
Crescent Biopharma & Nuvectis Pharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.